Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Operating Leases (2021 - 2025)

Vivos Therapeutics' Operating Leases history spans 5 years, with the latest figure at $3.8 million for Q4 2025.

  • Quarterly results put Operating Leases at $3.8 million for Q4 2025, up 271.01% from a year ago — trailing twelve months through Dec 2025 was $3.8 million (up 271.01% YoY), and the annual figure for FY2025 was $3.8 million, up 271.01%.
  • Operating Leases for Q4 2025 was $3.8 million at Vivos Therapeutics, up from $2.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.8 million in Q4 2025 to a low of $641000.0 in Q4 2021.
  • The 5-year median for Operating Leases is $1.9 million (2024), against an average of $1.9 million.
  • Peak annual rise in Operating Leases hit 271.01% in 2025, while the deepest fall reached 50.48% in 2025.
  • Year by year, Operating Leases stood at $641000.0 in 2021, then surged by 211.08% to $2.0 million in 2022, then decreased by 23.72% to $1.5 million in 2023, then plummeted by 31.95% to $1.0 million in 2024, then surged by 271.01% to $3.8 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $3.8 million, $2.9 million, and $2.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.